Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2021; 27(41): 7113-7124
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7113
Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena
Mercedes Perez-Carreras, Begoña Casis-Herce, Inmaculada Fernandez, Pilar Martinez-Montiel, Gastroenterology and Hepatology Unit, 12 de Octubre Universitary Hospital, Madrid 28041, Spain
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena, Faculty of Medicine, Complutense University, Madrid 28040, Spain
Raquel Rivera, Dermatology Department, 12 de Octubre Universitary Hospital, Madrid 28041, Spain
Victoria Villena, Pneumology Service, 12 de Octubre Universitary Hospital, Madrid 28041, Spain
Author contributions: Perez-Carreras M coordinated the review and wrote the majority of the article; Casis-Herce B and Martinez-Montiel P contributed to writing of the content on inflammatory bowel disease; Fernandez I contributed to writing of the content on non-alcoholic fatty liver disease; Rivera R contributed to writing of the content on psoriasis; Villena V contributed to writing of the content on obstructive apnea syndrome; and all authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mercedes Perez-Carreras, MD, PhD, Associate Professor, Medical Specialist. Gastroenterology and Hepatology Unit, 12 de Octubre Universitary Hospital, Av. de Córdoba s/n, Madrid 28041, Spain. mpcarreras@salud.madrid.org
Received: May 20, 2021
Peer-review started: May 20, 2021
First decision: June 12, 2021
Revised: July 4, 2021
Accepted: September 16, 2021
Article in press: September 16, 2021
Published online: November 7, 2021
Processing time: 169 Days and 11.9 Hours
Core Tip

Core Tip: Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common cause of liver disease. Its prevalence is increasing in parallel with the obesity and type 2 diabetes mellitus epidemics in developed countries. Several recent studies have suggested that NAFLD may be the hepatic manifestation of a systemic inflammatory metabolic disease that also affects other organs. This article reviews the currently available literature on issues relating to the co-existence of NAFLD and inflammatory bowel disease, obstructive syndrome apnea or psoriasis, with particular focus on the prevalence, risk factors and impact on clinical multidisciplinary management.